Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.
Bonny C, Fontaine H, Poynard T, Hézode C, Larrey D, Marcellin P, Bourlière M, Bronowicki JP, Merle P, Zarski JP, Sapey T, Guillemard C, Ughetto S, Henquell C, Nicolas C, Roche C, Randl K, Bommelaer G, Abergel A. Bonny C, et al. Among authors: bourliere m. Aliment Pharmacol Ther. 2006 Aug 15;24(4):593-600. doi: 10.1111/j.1365-2036.2006.03018.x. Aliment Pharmacol Ther. 2006. PMID: 16907892 Free article.
A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
Pol S, Couzigou P, Bourlière M, Abergel A, Combis JM, Larrey D, Tran A, Moussalli J, Poupon R, Berthelot P, Bréchot C. Pol S, et al. Among authors: bourliere m. J Hepatol. 1999 Jul;31(1):1-7. doi: 10.1016/s0168-8278(99)80157-3. J Hepatol. 1999. PMID: 10424277 Clinical Trial.
[Hepavir, the first observational study of one cohort of patients treated with alpha-2a interferon, monotherapy. Evaluation of asthenia and its social consequences].
Roudot-Thoraval F, Abergel A, Allaert F, Bourlière M, Desmorat H, Fagnani F, Fontanges T, Hanana A, Pol S, Zarski JP, Rousseaux C, Gandossi C, Samelson L, Dole S, Dantin S, Eberlé F, Saint-Marc-Girardin MF; Groupe d'Etude Pour Hépavir. Roudot-Thoraval F, et al. Among authors: bourliere m. Gastroenterol Clin Biol. 2001 Dec;25(12):1061-6. Gastroenterol Clin Biol. 2001. PMID: 11910986 Free article. French.
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
de Lédinghen V, Trimoulet P, Winnock M, Foucher J, Bourlière M, Desmorat H, Canva V, Capron D, Lévy S, Mion F, Mannant PR, Chêne G, Fleury H, Couzigou P, Bernard PH; French Multicenter Study Group. de Lédinghen V, et al. Among authors: bourliere m. J Hepatol. 2002 May;36(5):672-80. doi: 10.1016/s0168-8278(02)00026-0. J Hepatol. 2002. PMID: 11983451 Clinical Trial.
The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case-control study.
Leroy V, Bourliere M, Durand M, Abergel A, Tran A, Baud M, Botta-Fridlund D, Gerolami A, Ouzan D, Halfon P, Zarski JP. Leroy V, et al. Among authors: bourliere m. Eur J Gastroenterol Hepatol. 2002 May;14(5):485-9. doi: 10.1097/00042737-200205000-00004. Eur J Gastroenterol Hepatol. 2002. PMID: 11984145 Clinical Trial.
Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
de Lédinghen V, Trimoulet P, Winnock M, Bernard PH, Bourlière M, Portal I, Rémy AJ, Szostak N, Lévy S, Tran A, Abergel A, Chêne G, Fleury H, Couzigou P; French Multicenter Study Group. de Lédinghen V, et al. Among authors: bourliere m. J Hepatol. 2002 Jun;36(6):819-26. doi: 10.1016/s0168-8278(02)00071-5. J Hepatol. 2002. PMID: 12044534 Clinical Trial.
Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels.
Renou C, Halfon P, Pol S, Cacoub P, Jouve E, Bronowicki JP, Arpurt JP, Rifflet H, Picon M, Causse X, Canva V, Denis J, Tran A, Bourliére M, Ouzan D, Pariente A, Dantin S, Alric L, Cartier V, Reville M, Caillat-Zucman S. Renou C, et al. Among authors: bourliere m. Gut. 2002 Oct;51(4):585-90. doi: 10.1136/gut.51.4.585. Gut. 2002. PMID: 12235085 Free PMC article.
360 results